Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-08-14 DOI:10.1080/10428194.2025.2540437

Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Hua-Jay J Cherng, Ahmed Sawas, Adrienne Phillips, Tsiporah Shore, Peter Martin, John P Leonard, Giorgio Inghirami, Koen van Besien, Barbara Pro, Jennifer E Amengual, Jia Ruan

{"title":"Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.","authors":"Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Hua-Jay J Cherng, Ahmed Sawas, Adrienne Phillips, Tsiporah Shore, Peter Martin, John P Leonard, Giorgio Inghirami, Koen van Besien, Barbara Pro, Jennifer E Amengual, Jia Ruan","doi":"10.1080/10428194.2025.2540437","DOIUrl":null,"url":null,"abstract":"Peripheral T-cell lymphoma (PTCL) is characterized by clinicopathologic heterogeneity with a frequently relapsing/refractory (R/R) course. The optimal sequencing and efficacy of novel agents and SCT in second-line and beyond remains yet to be determined. The objective of this dual-institution retrospective study is to assess outcomes in R/R nodal PTCL with respect to SCT and novel agents. A total of 148 patients were reviewed for baseline characteristics and treatment parameters. Endpoints were subsequent EFS (sEFS) and subsequent overall survival (sOS). The median sEFS and sOS for the entire cohort was 5.3 m (95% CI: 4.1 - 7.1) and 32.4 m (95% CI: 17.7 - 71.0), respectively. The median sEFS favored patients who received salvage SCT following either chemotherapy or novel agents (p = 0.005). The median sOS showed similar trend. Altogether, these data suggest that incorporation of novel agents in patients with and without SCT in second-line and beyond may improve outcomes compared to historical cohorts.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2540437","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Peripheral T-cell lymphoma (PTCL) is characterized by clinicopathologic heterogeneity with a frequently relapsing/refractory (R/R) course. The optimal sequencing and efficacy of novel agents and SCT in second-line and beyond remains yet to be determined. The objective of this dual-institution retrospective study is to assess outcomes in R/R nodal PTCL with respect to SCT and novel agents. A total of 148 patients were reviewed for baseline characteristics and treatment parameters. Endpoints were subsequent EFS (sEFS) and subsequent overall survival (sOS). The median sEFS and sOS for the entire cohort was 5.3 m (95% CI: 4.1 - 7.1) and 32.4 m (95% CI: 17.7 - 71.0), respectively. The median sEFS favored patients who received salvage SCT following either chemotherapy or novel agents (p = 0.005). The median sOS showed similar trend. Altogether, these data suggest that incorporation of novel agents in patients with and without SCT in second-line and beyond may improve outcomes compared to historical cohorts.

查看原文本刊更多论文

现代复发/难治性外周t细胞淋巴瘤的预后：干细胞移植和新药物的影响

外周t细胞淋巴瘤（PTCL）具有临床病理异质性，病程常复发/难治。新药物和SCT在二线及以上的最佳排序和疗效仍有待确定。这项双机构回顾性研究的目的是评估与SCT和新型药物相关的R/R淋巴结PTCL的预后。148例患者的基线特征和治疗参数被回顾。终点是随后的EFS （sEFS）和随后的总生存期（sOS）。整个队列的中位sEFS和sOS分别为5.3 m （95% CI: 4.1 - 7.1）和32.4 m （95% CI: 17.7 - 71.0）。中位sEFS有利于化疗或新药物后接受补救性SCT的患者（p = 0.005）。sOS的中位数也显示出类似的趋势。总之，这些数据表明，与历史队列相比，在二线及以上的SCT患者中合并新药物可能会改善结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor